SYRE Q3 2024 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$55M

Net Income

-$69M

EPS (Diluted)

$-1.36

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$421M

Total Liabilities

$94M

Stockholders' Equity

$327M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$55M	-$18M	-202.1%
Net Income	-$69M	-$40M	-72.1%